our Premium Content: News alerts, weekly reports and conference planners

GENE:

JAK2 (Janus kinase 2)

News alerts, weekly reports and conference planners

Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report. (PubMed, Cancer Rep (Hoboken))

We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

2 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 mutation

Darzalex (daratumumab)

Diagnosis and Treatment of Polycythemia Vera: A Review. (PubMed, JAMA)

Ruxolitinib is a Janus kinase inhibitor that can alleviate pruritus and decrease splenomegaly in patients who are intolerant of or resistant to hydroxyurea. To decrease the risk of thrombosis, all patients with PV should be treated with aspirin and therapeutic phlebotomy to maintain a hematocrit of less than 45%. Cytoreductive therapies, such as hydroxyurea or interferon, are recommended for patients at high risk of thrombosis.

2 days ago

Review • Journal

JAK2 (Janus kinase 2)

Jakafi (ruxolitinib) • hydroxyurea • aspirin

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. (PubMed, J Hematol Oncol)

In a multivariate analysis, grade 2-3 MF (HR 2.0, 95%CI 1.59-2.51) was the strongest prognostic factor for survival. In summary, grade 2-3 MF in AML is associated with worse outcomes.

3 days ago

Retrospective data • Journal

IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • JAK2 (Janus kinase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

JAK2 mutation

Insight into the molecular mechanism of anti-breast cancer therapeutic potential of substituted salicylidene-based compounds using cell-based assays and molecular docking studies. (PubMed, Eur J Pharmacol)

Molecular docking studies revealed that selected protein targets strongly interact with bioactive compounds, and the estimated inhibition constants (Ki) of JAK2, STAT3, COX-2, HPV31 E6, EGFR1, TP53, and PARP1 were significantly decreased compared to acetylsalicylic acid. This could be a clear indication that these protein targets are implicated with antiproliferative efficacy, thereby warranting the potential of (1) and (7) to be used as anti-breast cancer drug candidates.

4 days ago

Journal • PARP Biomarker

TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1)

TP53 expression

aspirin

Harnessing Tumor Cell-Derived Exosomes for Immune Rejection Management in Corneal Transplantation. (PubMed, Adv Sci (Weinh))

Proteomic analyses reveal differential expression of pivotal proteins in B16-Exo, notably the JAK2 protein within the JAK-STAT signaling pathway, which has been mechanistically demonstrated to amplify the activity of myeloid-derived suppressor cells (MDSCs) and inhibit T cell proliferation. These findings demonstrate the significant immunomodulatory effect of B16-Exo in transplant immunology, supporting the continued exploration of tumor-derived exosomes as a platform to uncover novel immunosuppressive mechanisms in transplantation.

5 days ago

Journal • Tumor cell

JAK2 (Janus kinase 2)

High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype. (PubMed, Cancer Cell Int)

Considering all these data, we can conclude that the expression of immunoregulatory genes depends on tumor phenotype and has potential clinical implications in BC patients.

5 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • JAK2 (Janus kinase 2) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2)

HER-2 positive • HER-2 negative • PD-1 expression • CTLA4 expression • PD-L2 expression

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib. (PubMed, Clin Lymphoma Myeloma Leuk)

These novel time-dependent transfusion burden analyses demonstrate that momelotinib is associated with anemia-related benefits in most patients and greater transfusion burden reduction versus comparators.

6 days ago

Journal

JAK2 (Janus kinase 2) • ACVR1 (Activin A Receptor Type 1)

Jakafi (ruxolitinib) • Ojjaara (momelotinib)

Pharmacological effects of koumine on acute lung injury in septic mice: From in vivo experiments and network pharmacology studies. (PubMed, Biochem Biophys Res Commun)

Network pharmacology analysis showed that 52 putative targets were relevant, and SLC6A4, HTR3A, JAK2 and JAK3 were the key targets. GO and KEGG pathway enrichment analysis showed that the related mechanisms involved neuroactive ligand-receptor interaction, calcium signaling pathway, serotonergic synapses, cholinergic synapses, etc. In summary, this study confirmed the potential therapeutic effect of koumine in sepsis induced ALI, suggesting its development prospect as a novel candidate drug for ALI, and providing data support.

7 days ago

Preclinical • Journal

JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • JAK3 (Janus Kinase 3) • IL1B (Interleukin 1, beta) • MPO (Myeloperoxidase) • SLC6A4 (Solute Carrier Family 6 Member 4)

JAK3 mutation

Performance of Pillar oncoReveal Essential MPN Panel: Experiences of Two Clinical Diagnostic Laboratories (AMP 2024)

This intra-laboratory study demonstrates that the oncoReveal Essential MPN Panel performed very well against comparator methods. The performance characteristics, workflow benefits, and TAT saving are suitable for clinical testing of MPN patient population to allow accurate clinical assessment.

8 days ago

Clinical

JAK2 (Janus kinase 2) • CALR (Calreticulin)

JAK2 V617F

ONCO/Reveal™ Essential MPN Panel

DNA and RNA NGS for Myeloid Neoplasms Using Oncomine Myeloid Assay GX v2 on GeneXus: An Assessment of Clinical Utility (AMP 2024)

This DNA- and RNA-based 80-gene panel has proven to be a powerful tool for genomic profiling of myeloid neoplasms. The results were provided to hematopathologists/oncologists in timely fashion with the critical information for diagnosis confirmation, and disease classification, as well as assessment of patient response to treatment.

8 days ago

Clinical • Next-generation sequencing

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • DDX41 (DEAD-Box Helicase 41) • CALR (Calreticulin) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

FLT3-ITD mutation • NPM1 mutation • U2AF1 mutation • CEBPA mutation • JAK2 V617F

Oncomine Myeloid Assay GX

Assessing the Efficacy of an MPN Panel: A 6-Month Retrospective Study and Follow-Up Testing with Pan-Heme Panel (AMP 2024)

The MPN NGS panel demonstrated excellent clinical utility, as 96% (26/27) of significant JAK2/CALR/MPL variants were identified in our cohort. The detection rate of predominately JAK2 variants with rare CALR and MPL variants is in line with the current literature. Based on the findings of patients that underwent the pan-heme panel, potential expansion of coverage regions in JAK2 to include additional exons (such as exon 16) could further improve the detection rate.

8 days ago

Retrospective data

JAK2 (Janus kinase 2) • CALR (Calreticulin)

FusionPlex™ Pan-Heme panel • PanHeme assay

Target-Capture Next-Generation Sequencing (NGS) for Use in Molecular-Based Research of Myeloid Measurable Residual Disease (MRD) (AMP 2024)

Target-capture NGS provides the opportunity to evaluate many genes in a single assay. Suitability for MRD requires highly uniform and sensitive target enrichment. Our study demonstrated reliable and accurate detection of variants down to 0.05% VAF, providing researchers with the capability to use capture-based NGS for myeloid MRD monitoring.

8 days ago

Next-generation sequencing

FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • JAK2 (Janus kinase 2)

FLT3-ITD mutation • NPM1 mutation • FLT3 D835Y • FLT3 D835 • IDH2 R172K • KIT D816V • IDH1 R132C • JAK2 V617F • IDH1 R132 • IDH2 R172

SureSeq™ Myeloid MRD Panel

14d

Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis. (PubMed, Front Pharmacol)

However, its potential synergistic effects with DDP (cisplatin) in breast cancer (BRCA) remain to be fully elucidated. In vivo study further support these results, showing that anlotinib markedly inhibits tumor growth in xenografted mice. This study confirms the efficacy of anlotinib or in combination with DDP and elucidates the mechanism behind anlotinib's effectiveness, highlighting its role in inhibiting the JAK2/STAT3 pathway.

14 days ago

Journal • BRCA Biomarker

JAK2 (Janus kinase 2) • BRCA (Breast cancer early onset)

VEGFA expression

cisplatin • Focus V (anlotinib)

14d

Emerging insights into epigenetics and hematopoietic stem cell trafficking in age-related hematological malignancies. (PubMed, Stem Cell Res Ther)

The involvement of age-induced genetic/epigenetic alterations in BM niche cells and immunological stressors in hematopoiesis is crucial for understanding the development of age-related hematological malignancies. This comprehensive review provides new insights into the complex interplay between niche cells and HSCs, emphasizing the potential for novel therapeutic approaches that target niche cell functionality and resilience to improve hematopoietic outcomes in the context of aging and metabolic disorders.

14 days ago

Review • Journal

DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

DNMT3A mutation • TET2 mutation

14d

Amide Functionalized Novel Pyrrolo-pyrimidine Derivative as Anticancer Agents: Synthesis, Characterization and Molecular Docking Studies. (PubMed, Anticancer Agents Med Chem)

The synthesized pyrazolo pyrimidine derivatives showed potential as lead compounds for further development due to their promising binding affinities and significant anticancer activity, particularly those with nitro and heterocyclic moieties.

14 days ago

Journal

JAK2 (Janus kinase 2) • CDK4 (Cyclin-dependent kinase 4) • JAK1 (Janus Kinase 1)

doxorubicin hydrochloride

15d

GHRH and the prostate. (PubMed, Rev Endocr Metab Disord)

Over the last fifty years, the development of GHRH-R receptor antagonists has been unstoppable, improving their potency, stability and affinity for the receptor. The last series of GHRH-R antagonists, AVR, exhibits superior anticancer and anti-inflammatory activities in both in vivo and in vitro assays.

15 days ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2) • JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)

15d

Development and Validation of a Biopsy-Free Scoring System for Screening Myelodysplastic Syndrome (MDS) and Associated Diseases in Cytopenic Patients (ASH 2024)

For patients with a probability score < 45%, a bone marrow study may not be needed, with a recommended follow-up every 6–12 months. This comprehensive analysis provides a useful and non-invasive predictive model that enhances diagnostic accuracy which potentially reduces unnecessary procedures.

15 days ago

Clinical • Biopsy

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • SETBP1 (SET Binding Protein 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

TP53 mutation • KRAS mutation • NRAS mutation • IDH2 mutation • NPM1 mutation • ASXL1 mutation • TET2 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • STAG2 mutation

Oncomine Myeloid Research Assay

15d

DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms (ASH 2024)

DTA mutations detected with a clinically used NGS panel in patients with MPN are associated with increased risk of bleeding complications, as well as increased thrombotic risk in a subgroup of patients. These findings support the incorporation of molecular panel analyses in thrombosis and bleeding risk assessment in MPN, and merit further investigation.

15 days ago

Clinical

DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CALR (Calreticulin)

DNMT3A mutation • ASXL1 mutation • TET2 mutation • JAK2 V617F • JAK2 mutation

Archer® VariantPlex® Myeloid panel

15d

Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse (ASH 2024)

Low T cell diversity is a marker of poor overall survival at relapse. These findings suggest T cell mediated immunity is critical for chemotherapy response in DLBCL and could have implications for predicting responses to newer T cell directed therapies such as bispecific T cell and CART therapies.

15 days ago

PD(L)-1 Biomarker • IO biomarker • Biopsy

CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD68 (CD68 Molecule) • CD7 (CD7 Molecule) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • RELA (RELA Proto-Oncogene) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)

nCounter® PanCancer Immune Profiling Panel

15d

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant (ASH 2024)

Blinatumomab was not used during consolidation therapy in the reported patients. Its incorporation in the routine therapy of newly diagnosed patients may increase the proportion of patients receiving AHCT in a MRD negative state and further improve outcomes in this historically poor risk patient population.

15 days ago

Clinical

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CRLF2 (Cytokine Receptor Like Factor 2) • CSF1R (Colony stimulating factor 1 receptor)

CRLF2 rearrangement • JAK2 rearrangement

clonoSEQ

Blincyto (blinatumomab)

15d

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms (ASH 2024)

Serial NGS-based studies in patients with TP53MT inform important clues to prognosis. While being a dominant or persistent TP53MT clone either at the same configuration or up-trending clonal burden post treatment equates to poor prognosis, it is crucial to study further those who display better clinical outcomes with standard-of-care treatment. Such information will be invaluable for making treatment decisions in this grave prognostic disease otherwise.

15 days ago

TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

TP53 mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation • SF3B1 mutation

TruSight Myeloid Sequencing Panel

15d

Comprehensive Genomic Profiling (CGP) of Acute Lymphoblastic Leukemias with Foundation One Heme Identifies Actionable Genomic Alterations and Biomarkers (ASH 2024)

This analysis of 2,637 samples comprising a variety of molecular subtypes of ALL demonstrated that the F1H assay detects pathogenic genomic alterations with diagnostic, prognostic, and therapeutic significance. As both the treatment landscape and disease classification system in ALL have continued to evolve over time, CGP assays such as F1H can play a critical role in clinical decision making by simultaneously assessing the presence and absence of numerous actionable genomic alterations and biomarkers with a single assay.

15 days ago

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • P2RY8 (P2Y Receptor Family Member 8) • PBX1 (PBX Homeobox 1) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)

TP53 mutation • KRAS mutation • NRAS mutation • PTEN mutation • CDKN2A deletion

FoundationOne® Heme CDx

21d

Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix. (PubMed, Int J Gynecol Pathol)

Next-generation sequencing of the 3 HER2-amplified tumors showed amplification of various genes, including CD274, JAK2, BIRC3, and ERBB2, and a PIK3CA missense mutation. In summary, HER2 immunohistochemistry is a reliable predictive marker of HER2 amplification in cervical cancer.

21 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • JAK2 (Janus kinase 2) • BIRC3 (Baculoviral IAP repeat containing 3)

HER-2 overexpression • HER-2 amplification • PIK3CA mutation

21d

Analysis of Incidence Rate, Risk Factors and Prognosis of Pulmonary Hypertension in Ph-MPNs Patients (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)

The incidence rate of PH in Ph- MPNs patients is high, and its risk factors are diverse. The OS rate of Ph- MPNs patients with PH is low. Therefore, we should be highly alert to the occurrence of PH in Ph- MPNs patients clinically.

21 days ago

Retrospective data • Journal

JAK2 (Janus kinase 2)

22d

JAK 2-Positive Diseases and Spontaneous Coronary Artery Dissection: Case Series. (PubMed, Case Rep Oncol)

MPNs with JAK2 mutations are associated with SCAD in addition to usual atherosclerosis. This association needs further research.

22 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

23d

CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia. (PubMed, Indian J Hematol Blood Transfus)

In conclusion, our study reveals that CSE1L is a potential therapeutic target for overcoming Ara-c resistance in AML cells. Thus, we have gained new insights into the oncogenic process of CSE1L in AML cells and raised the prospect of knockdown of CSE1L in AML in combination with cytarabine-targeted therapy.

23 days ago

Journal

JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)

JAK2 overexpression

cytarabine

23d

LncRNA BRE-AS1 regulates the JAK2/STAT3-mediated inflammatory activation via the miR-30b-5p/SOC3 axis in THP-1 cells. (PubMed, Sci Rep)

Conversely, a miR-30b-5p mimic replicated the BRE-AS1 attenuation outcomes. Our findings elucidate the role of lncRNA BRE-AS1 in modulating inflammatory activation in THP-1 cells via the miR-30b-5p/SOCS3/JAK2/STAT3 signaling pathway, proposing that manipulation of macrophage BRE-AS1 activity may offer a novel therapeutic avenue in diseases characterized by macrophage-driven pathogenesis.

23 days ago

Journal

JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR30B (MicroRNA 30b) • IL1B (Interleukin 1, beta) • SOCS3 (Suppressor Of Cytokine Signaling 3)

24d

Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

CVR/SOR is a powerful combination for tumor repression and enhancing SOR efficiency in HCC by modulating FGL1. Moreover, CVR/SOR might exert the aforementioned effects through HIF-1α/STAT3/FGL1 pathway.

24 days ago

Preclinical • Journal

JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CREBBP (CREB binding protein) • FGL1 (Fibrinogen Like 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)

HIF1A expression

sorafenib

24d

Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience. (PubMed, Medicine (Baltimore))

According to early findings, NGS panels are extremely effective instruments that provide an entirely new viewpoint on the disease for particular individuals. Future prognostications will depend more on NGS because those who exhibit normal cytogenetics may additionally have gene mutations.

24 days ago

Journal • Next-generation sequencing

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SETBP1 (SET Binding Protein 1) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6)

ASXL1 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • PHF6 mutation

25d

Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. (PubMed, J Clin Exp Hematop)

Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.

25 days ago

Journal

JAK2 (Janus kinase 2) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MAPK1 (Mitogen-activated protein kinase 1) • VEGFC (Vascular Endothelial Growth Factor C) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL18BP (Interleukin 18 Binding Protein) • IL1R1 (Interleukin 1 receptor, type I) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • NFKBIA (NFKB Inhibitor Alpha 2) • STAT2 (Signal transducer and activator of transcription 2) • IL3 (Interleukin 3) • IL33 (Interleukin 33) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9) • PDGFC (Platelet Derived Growth Factor C) • TNFAIP8 (TNF Alpha Induced Protein 8) • MAPK10 (Mitogen-Activated Protein Kinase 10)

25d

Features and allele frequency of JAK2 Exon 12-mutated polycythemia vera in comparison with JAK2V617F-mutated disease. (PubMed, Arch Med Res)

Taiwanese patients with PV showed differences in blood count, risk group, and bleeding events between exon 12 and JAK2V617F patients. Higher mutant allele burden had a negative impact on overall survival for both mutation types.

25 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

26d

Napabucasin Inhibits Proliferation and Migration of Glioblastoma Cells (U87) by Regulating JAK2/STAT3 Signaling Pathway. (PubMed, Medicina (Kaunas))

In this study, the anti-proliferative and apoptotic effects of NP and the chemotherapy agent doxorubicin (DX), a natural compound, on glioblastoma cells (U87) were investigated. Since it can suppress Jak2/Stat3, an important cancer cell proliferation pathway in glioblastoma, the combination of NP and DX can be used as an alternative treatment agent. But no synergistic effect of NP and DX on the U87 cells of the glioblastoma cell line was observed.

26 days ago

Journal

JAK2 (Janus kinase 2)

STAT3 expression

doxorubicin hydrochloride • napabucasin (BBI608)

26d

Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis. (PubMed, Int J Mol Sci)

Naringin also demonstrated the ability to inhibit DNCB-induced changes in interleukin (IL) 4, chemokine (C-C motif) ligand (CCL) 17, CCL22, IL1β, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels by quantitative real-time polymerase chain reaction (qRT-PCR) and IL13 by enzyme-linked immunosorbent assay (ELISA) (p < 0.05). Western blot results exhibited the decreased JAK1, JAK2, STAT1, STAT3, phospho-STAT3, and STAT6 expression in the naringin-treated groups (p < 0.05); The findings of this study suggest that topical naringin may effectively improve the symptoms of AD and could be used as a therapeutic agent for AD.

26 days ago

Journal

JAK2 (Janus kinase 2) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CCL2 (Chemokine (C-C motif) ligand 2) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • CCL22 (C-C Motif Chemokine Ligand 22) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta)

29d

CLINICAL AND LABORATORY CHARACTERISTICS OF THE LATENT FORM OF POLYCYTHEMIA VERA. (PubMed, Georgian Med News)

According to the obtained results, it can be concluded that timely and correct diagnosis of LPV is very important. Despite the fact that disease passes in a latent, masked form, THC are more likely to occur. This can be attributed to the high platelet count in the blood and the lack of timely treatment of the disease.

29 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 mutation

29d

EXCEED ET: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET (clinicaltrials.gov)

P2, N=91, Active, not recruiting, PharmaEssentia | Recruiting --> Active, not recruiting | N=64 --> 91 | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Jul 2024 --> Mar 2027

29 days ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date

JAK2 (Janus kinase 2)

JAK2 mutation

Besremi (ropeginterferon alfa-2b-njft)

Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology. (PubMed, Cell Commun Signal)

Current therapeutic strategies include JAK inhibitors like Ruxolitinib, which target the JAK-STAT pathway, alongside supportive treatments such as blood transfusions, erythropoiesis-stimulating agents and developing combinatorial approaches...Recently approved JAK inhibitors, including Fedratinib, Pacritinib, and Momelotinib, have expanded the therapeutic landscape...These technologies elucidate the role of the spleen in MF, highlighting its transformation into a site of abnormal hematopoietic activity, fibrotic changes, and immune cell infiltration, functioning as a "tumor surrogate." By profiling diverse cell populations and molecular alterations within the BM and spleen, SRT facilitates a deeper understanding of MF pathophysiology, helping identify novel therapeutic targets and biomarkers. Ultimately, integrating spatial transcriptomics into MF research promises to enhance diagnostic precision and therapeutic innovation, addressing the multifaceted challenges of this disease.

1 month ago

Review • Journal

TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • TET2 (Tet Methylcytosine Dioxygenase 2) • TNFA (Tumor Necrosis Factor-Alpha) • SRSF2 (Serine and arginine rich splicing factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • CALR (Calreticulin)

TP53 mutation • TET2 mutation • SRSF2 mutation

Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)

JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β. (PubMed, J Cell Mol Med)

In conclusion, we show a JAK2-dependent down regulation of SHP-1 in MPN patients' cells which is related to their resistance to the antiproliferative effect of TGF-β. This may participate in the clonal selection of cancer cells in MPNs.

1 month ago

Journal

JAK2 (Janus kinase 2) • CD34 (CD34 molecule) • TGFB1 (Transforming Growth Factor Beta 1)

JAK2 V617F • CD34 positive

Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report. (PubMed, Cureus)

Antiplatelet therapy was started with acetylsalicylic acid 100 mg and clopidogrel 75 mg once a day. With the recommendation of hematology, cytoreductive treatment, hydroxyurea 1000 mg twice a day, was started. The patient's complaints were resolved at the end of the second day, and the patient with minimal ataxia was discharged with recommendations. Patients with ET should be aware of ischemic cerebrovascular disease and consider antiplatelet and cytoreductive treatment options.

1 month ago

Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

hydroxyurea

Analysis of the Plasticity of Circulating Tumor Cells Reveals Differentially Regulated Kinases During the Suspension-to-Adherent Transition. (PubMed, Cancer Med)

The investigated CTC lines exhibit a high plasticity, similar to the concept of 'adherent-to-suspension transition (AST)' that was recently suggested as a new hallmark of tumor biology by Huh et al. Moreover, we identified differentially regulated kinome profiles that may represent potential targets for future studies on therapeutic interventions.

1 month ago

Journal • Circulating tumor cells • Tumor cell

JAK2 (Janus kinase 2)

Systemic ALK-Negative Anaplastic Large Cell Lymphoma: Insights into Morphologic, Immunophenotypic, Genetic and Molecular Characteristics. (PubMed, Hum Pathol)

Gene expression profiling data have shownthat ALK-negative ALCL has distinctive molecular signatures, different from ALK+ ALCL and other T-cell lymphomas. Better understanding of the morphologic, immunophenotypic, genetic and molecular features of ALK-negative ALCL will help establish the correct diagnosis, guide therapeutic strategies and improve patient outcomes.

1 month ago

Journal

ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • JAK2 (Janus kinase 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TYK2 (Tyrosine Kinase 2) • TP63 (Tumor protein 63) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)

ALK positive • ALK rearrangement • TNFRSF8 expression • ALK negative • STAT3 mutation • JAK1 mutation

Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review. (PubMed, Cureus)

PV patients with high risk can benefit from low-dose aspirin...Patients with polycythemia vera can present with a high or low serum EPO level. Further diagnostic tests are usually required to confirm the final diagnosis.

1 month ago

Review • Journal

JAK2 (Janus kinase 2)

JAK2 mutation

aspirin

Absence of canonical mutations in pediatric essential thrombocytosis: a case series. (PubMed, Blood Res)

No patient experienced hemorrhagic or thrombotic complications. Our case series emphasizes that the genetic features of pediatric ET may differ significantly from those of adult ET, and that treatment cessation is a possibility for some patients.

1 month ago

Journal

JAK2 (Janus kinase 2) • CALR (Calreticulin)

JAK2 V617F